Research Progress of Lung Cancer Vaccines.
10.3779/j.issn.1009-3419.2023.106.19
- Author:
Hao FAN
1
;
Xiangwei GE
1
;
Xin ZHOU
1
;
Yao LI
1
;
An WANG
1
;
Yi HU
2
Author Information
1. Chinese PLA Medical School, Beijing 100853, China.
2. Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China.
- Publication Type:Journal Article
- Keywords:
Cancer vaccine;
Lung neoplasms;
New antigen;
Next-generation sequencing
- MeSH:
Humans;
Cancer Vaccines/therapeutic use*;
Antigens, Neoplasm;
Lung Neoplasms/drug therapy*;
Neoplasms/genetics*;
Computational Biology;
Immunotherapy/methods*;
Lung
- From:
Chinese Journal of Lung Cancer
2023;26(9):692-700
- CountryChina
- Language:Chinese
-
Abstract:
With the development of medical technology, tumor vaccines as a novel precise immunotherapy approach have gradually received attention in clinical applications. Against the backdrop of the global corona virus disease 2019 (COVID-19) outbreak, vaccine technology has further advanced. Depending on the types of antigens, tumor vaccines can be divided into whole-cell vaccines, peptide vaccines, messenger ribonucleic acid (mRNA) vaccines, recombinant virus vaccines, etc. Although some tumor vaccines have been marketed and achieved certain therapeutic effects, the results of tumor vaccines in clinical trials have been unsatisfactory in the past period. With the maturation of next-generation sequencing (NGS) technology and the continuous development of bioinformatics, dynamic monitoring of the entire process of tumor subpopulation development has become a reality, which has laid a solid foundation for personalized, neoantigen-centered therapeutic tumor vaccines. This article reviews the recent developments of tumor vaccines of different types, starts with lung cancer and summarizes the achievements of tumor vaccines in clinical applications, and provides an outlook for the future development of antigen-centered tumor vaccines.
.
